Oncode is the independent institute dedicated to outsmarting cancer and impacting lives.
Carl Figdor and Michiel Vermeulen participate in the Oncode Institute for Radboudumc and Radboud University, respectively.
Research programmeDespite enormous progress in our understanding of cancer, the chance of long-term survival remains small for many patients, particularly those with metastatic disease. Oncode will address this unmet clinical need through an innovative basic research programme. True innovation in the treatment of cancer relies on new insights into the basic mechanisms of oncogenesis, which in turn depend heavily on technological innovation. Oncode research will be guided by a number of key questions that need to be resolved to extend life expectancy and improve quality of life for cancer patients.
Principal scientific questionsThe key issues in cancer research today are summed up in our principal scientific questions:
- Can we define new and better targets for therapy on the basis of detailed analyses of tumours, tumour-derived cell lines and organoids, and xenografts?
- What is the basis for tumour heterogeneity, and how can we harness this knowledge to refine cancer therapy?
- What role does the cell of origin play in a tumour’s characteristics and responsiveness to therapy?
- How do cancer cells avoid host immune attack, and how can we stop them from doing so?
- How do non-mutated background genes influence tumour formation and response to therapy?
- Can we develop novel models to predict therapy response?
- How can we prevent metastatic disease?
Scientific themesOn the basis of these questions, Oncode’s founding scientists have identified six scientific themes that constitute the basis of the integrated research strategy:
- Development of novel technologies
- Understanding the critical drivers of tumour growth and the causes of resistance
- Analysis of network perturbations in tumours and tumour-host interactions
- Causes and consequences of genetic instability
- Identification of critical drug combinations and biomarkers for personalized cancer treatments
- Mobilizing immune defence
Read more on the Oncode website.
Related news items
Surgery to straighten a deviated septum improves quality of life20 June 2019
Patients with a deviated septum breathe more easily after a septoplasty and their quality of life improves. Specialists have long debated its benefits. Machteld van Egmond, Maroeska Rovers, and Niels van Heerbeek have ended the controversy with a publication in The Lancet.read more
A personal touch of Jaap ten Oever20 June 2019
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Jaap ten Oever.read more
Development of nationwide recommendations to support prenatal counseling in extreme prematurity20 June 2019
In Pediatrics Rosa Geurtzen et al described the development of a nationwide, evidence-based framework for prenatal counseling in extreme prematurity. It contains recommendations and tools for personalization in the domains of organization, decision-making, content, and style of prenatal counseling.read more
Remote Ischemic Conditioning as a new treatment for ischemic stroke20 June 2019
In Stroke Thijs Landman and colleagues described the existing clinical and preclinical evidence for a new non-invasive treatment in patients with an ischemic stroke: Remote Ischemic Conditioning.read more
Radboudumc Master Prize for Mark van Goor18 June 2019
Mark van Goor, theme Renal disorders, received the Radboudumc Master Prize for his MSc thesis entitled “High-resolution structure of the renal calcium channel TRPV5 revealed with cryo-EM”, which was based on his internship at the lab of Prof. Yifan Cheng, USA.read more